Biosimilar Sponsors Want Off-The-Record Labeling Discussions With US FDA
Executive Summary
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions written record; negotiations for BsUFA III may be opportunity to create such a process.
You may also be interested in...
BsUFA III: Reauthorization Process Begins With US FDA Considering Staffing, Uptake Issues
Biosimilar availability may not be in the its purview, but the FDA still is thinking about ways to help industry deal with the issue and support sector growth.
FDA Guides On Adding Biosimilar Indications
Sponsors may submit supplemental applications for additional indications in advance so that approval will coincide with expiration of a reference product’s exclusivity or patent protection, new draft guidance states; agency targets six-month review of such supplements, rather than the 10 months provided under BsUFA II.
Biosimilars: US FDA Proposes Streamlined Pathway For Indication Carve-Ins
Sponsors may submit supplemental applications for additional indications in advance so that approval will coincide with expiration of a reference product’s exclusivity or patent protection, new draft guidance states; agency targets six-month review of such supplements, rather than the 10 months provided under BsUFA II.